FIELD: pharmacology, medicine.
SUBSTANCE: claimed invention discloses the use of the compound of tris-(2-hydroxyethyl)ammonium salt of 1-benzylindolyl-3-thioacetic acid as an inhibitor of the activity of the endogenous human retrovirus HERV-E λ 4-1env in peripheral blood mononuclear cells and cerebrospinal fluid mononuclear cells in multiple sclerosis.
EFFECT: technical result of the invention is a positive effect that inhibits the activity of an endogenous retrovirus when using tris-(2-hydroxyethyl)ammonium salt of 1-benzylindolyl-3-thioacetic acid in multiple sclerosis.
1 cl, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIRETROVIRAL DRUG AIMED AT HUMAN ENDOGENOUS RETROVIRUS | 2015 |
|
RU2689326C1 |
| COMPOUNDS FOR REMYELINATION BLOCKADE TREATMENT IN DISEASES RELATED TO EXPRESSION OF HERV-W SHELL PROTEIN | 2013 |
|
RU2636355C2 |
| METHOD FOR TREATING AUTOIMMUNE DISEASES | 2003 |
|
RU2252760C1 |
| METHOD FOR OBTAINING OF 1-R-INDOLE-3-YLSULFANYLACETATES OF (2-HYDROXYETHYL)AMMONIUM | 2016 |
|
RU2642778C2 |
| RELEASE AND IDENTIFICATION OF T-CELLS | 2003 |
|
RU2327487C2 |
| METHOD FOR PRODUCTION OF POLYCLONAL T-CELL VACCINE USEFUL IN TREATMENT OF IMMUNOLOGICAL DISORDERS | 2004 |
|
RU2277422C2 |
| METHOD FOR PREDICTING OPTIC NEURITIS FLOW AT MULTIPLE SCLEROSIS | 2001 |
|
RU2200326C2 |
| METHOD OF THERAPY OF REMITTENT MULTIPLE SCLEROSIS | 2012 |
|
RU2523058C2 |
| IMMUNOSUPRESSOR | 2003 |
|
RU2253448C1 |
| FATTY ACID ANALOGS FOR TREATING INFLAMMATORY AND AUTOIMMUNE DISORDERS | 2001 |
|
RU2259823C2 |
